High Tide Announces Preliminary Q3 2026 Guidance
High Tide Inc. (Nasdaq: HITI) issued preliminary guidance for its fiscal Q3 ended July 31, 2026, expecting record revenue, gross profit and adjusted EBITDA, with year-over-year growth of at least 30%, 27% and 43%, respectively. It also reported Remexian Pharma distributed over 10 tonnes of medical cannabis in Germany, up 33% sequentially and 60% year over year. Full results are due Sept. 14, 2026.
How this was made
The 30-second read
Why it matters
The company’s preliminary Q3 2026 guidance sets expectations for record revenue, gross profit, and Adjusted EBITDA, and attributes performance to improving Canadian same-store sales and scaling German medical cannabis distributions.
Market read
This is a quantified guidance update that can shift consensus expectations ahead of the scheduled Sept 14 after-hours Q3 results.
What to watch
The release does not provide detailed assumptions (pricing, margin drivers, regulatory constraints, or store-level metrics beyond same-store sales direction), so traders should watch for reconciliation in the Sept 14 full report.
Background
High Tide is a retail-forward cannabis operator (Canna Cabana) with a German medical cannabis distribution business via Remexian Pharma GmbH.
Ticker impact
High Tide issues preliminary Q3 2026 guidance calling for record revenue, gross profit, and Adjusted EBITDA, with YoY growth of at least 30%/27%/43%.
Likely positive bias for HITI shares into the Sept 14 after-hours earnings print, with volatility around whether the final numbers confirm the “low end beats consensus” claim.
The article is a first disclosure of quantified guidance and includes specific YoY growth rates and a statement that even the low end exceeds the highest current analyst estimate across the three metrics. However, it is still preliminary and not the final financials.
Market effects
Supports the narrative of improving profitability and operating leverage in Canadian cannabis retail and German medical distribution.
Reinforces positive read-through for Canada cannabis retail demand and Germany medical cannabis supply/distribution scaling.
Highlights cross-border scaling (Canada retail plus Germany medical distribution) as a potential model for global cannabis operators.
Counterpoint
Preliminary guidance may be optimistic; if final Q3 results or margins disappoint, the stock could retrace quickly after the initial enthusiasm.
Key entities
- public_companyHigh Tide Inc.
Nasdaq-listed cannabis enterprise providing preliminary Q3 2026 guidance and distribution updates.
- subsidiaryRemexian Pharma GmbH
German medical cannabis distribution business referenced for record quarterly shipments of over 10 tonnes.
